JP2017538407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538407A5 JP2017538407A5 JP2017529043A JP2017529043A JP2017538407A5 JP 2017538407 A5 JP2017538407 A5 JP 2017538407A5 JP 2017529043 A JP2017529043 A JP 2017529043A JP 2017529043 A JP2017529043 A JP 2017529043A JP 2017538407 A5 JP2017538407 A5 JP 2017538407A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- disease
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 76
- 229920001184 polypeptide Polymers 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 71
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 150000001413 amino acids Chemical class 0.000 claims description 47
- 238000006467 substitution reaction Methods 0.000 claims description 46
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 28
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 206010012289 Dementia Diseases 0.000 claims description 11
- 230000013595 glycosylation Effects 0.000 claims description 11
- 238000006206 glycosylation reaction Methods 0.000 claims description 11
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 8
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 6
- 102220004796 rs104893939 Human genes 0.000 claims description 6
- 102000013498 tau Proteins Human genes 0.000 claims description 6
- 108010026424 tau Proteins Proteins 0.000 claims description 6
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000010291 Primary Progressive Nonfluent Aphasia Diseases 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000018642 Semantic dementia Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 4
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 231100000518 lethal Toxicity 0.000 claims description 4
- 230000001665 lethal effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 102220614638 Queuine tRNA-ribosyltransferase accessory subunit 2_T41R_mutation Human genes 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 102200044888 rs121913412 Human genes 0.000 claims description 3
- 102200044889 rs121913413 Human genes 0.000 claims description 3
- 102220198148 rs121913413 Human genes 0.000 claims description 3
- 102220054831 rs727503062 Human genes 0.000 claims description 3
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims description 2
- 102000007372 Ataxin-1 Human genes 0.000 claims description 2
- 108010032963 Ataxin-1 Proteins 0.000 claims description 2
- 102000014461 Ataxins Human genes 0.000 claims description 2
- 108010078286 Ataxins Proteins 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 2
- 102000012192 Cystatin C Human genes 0.000 claims description 2
- 108010061642 Cystatin C Proteins 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 206010016202 Familial Amyloidosis Diseases 0.000 claims description 2
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims description 2
- 206010018341 Gliosis Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 208000024571 Pick disease Diseases 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 2
- 230000003542 behavioural effect Effects 0.000 claims description 2
- 230000002308 calcification Effects 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 208000035850 clinical syndrome Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 230000007387 gliosis Effects 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 206010023497 kuru Diseases 0.000 claims description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 2
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 210000000463 red nucleus Anatomy 0.000 claims description 2
- 102220276815 rs201708813 Human genes 0.000 claims description 2
- 208000008864 scrapie Diseases 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims description 2
- 230000002739 subcortical effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 3
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 3
- 102100034452 Alternative prion protein Human genes 0.000 claims 2
- 102100028953 Gelsolin Human genes 0.000 claims 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims 2
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 108090001064 Gelsolin Proteins 0.000 claims 1
- 101001059150 Homo sapiens Gelsolin Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 208000022435 Light chain deposition disease Diseases 0.000 claims 1
- 208000020647 Light chain disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 241000232971 Passer domesticus Species 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000001898 pallidal effect Effects 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087052P | 2014-12-03 | 2014-12-03 | |
| US62/087,052 | 2014-12-03 | ||
| PCT/US2015/063476 WO2016090022A1 (en) | 2014-12-03 | 2015-12-02 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020026300A Division JP2020073610A (ja) | 2014-12-03 | 2020-02-19 | グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538407A JP2017538407A (ja) | 2017-12-28 |
| JP2017538407A5 true JP2017538407A5 (enExample) | 2019-01-10 |
| JP6730988B2 JP6730988B2 (ja) | 2020-07-29 |
Family
ID=55273507
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529043A Active JP6730988B2 (ja) | 2014-12-03 | 2015-12-02 | グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
| JP2020026300A Withdrawn JP2020073610A (ja) | 2014-12-03 | 2020-02-19 | グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020026300A Withdrawn JP2020073610A (ja) | 2014-12-03 | 2020-02-19 | グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10722551B2 (enExample) |
| EP (1) | EP3227313B1 (enExample) |
| JP (2) | JP6730988B2 (enExample) |
| KR (1) | KR20170085132A (enExample) |
| CN (1) | CN107250154A (enExample) |
| AR (1) | AR102890A1 (enExample) |
| AU (1) | AU2015358504A1 (enExample) |
| BR (1) | BR112017011530A2 (enExample) |
| CA (1) | CA2969128A1 (enExample) |
| DK (1) | DK3227313T3 (enExample) |
| EA (1) | EA201791212A1 (enExample) |
| ES (1) | ES2910017T3 (enExample) |
| IL (1) | IL252426A0 (enExample) |
| MX (1) | MX2017007059A (enExample) |
| PH (1) | PH12017501004A1 (enExample) |
| PL (1) | PL3227313T3 (enExample) |
| PT (1) | PT3227313T (enExample) |
| SG (1) | SG11201704427YA (enExample) |
| TW (1) | TW201632542A (enExample) |
| WO (1) | WO2016090022A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2785364B1 (en) | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
| MX358755B (es) | 2012-10-02 | 2018-09-03 | Proclara Biosciences Inc | Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides. |
| US9988444B2 (en) | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| SG11201704427YA (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences Inc | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
| US11692017B2 (en) | 2018-06-15 | 2023-07-04 | Amyl Therapeutics Srl | General amyloid interaction motif (GAIM) |
| KR20250110352A (ko) | 2022-12-02 | 2025-07-18 | 알제온, 인크. | 트라미프로세이트를 이용하여 신경퇴행성 장애를 치료하는 방법 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| KR20030082962A (ko) | 2001-03-08 | 2003-10-23 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ) |
| DE10238846A1 (de) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| JP5096169B2 (ja) | 2005-02-01 | 2012-12-12 | ラモット・アット・テルアビブ・ユニバーシティ | アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 |
| AU2007214399A1 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel-Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| WO2007094003A2 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| US20090105090A1 (en) | 2006-04-06 | 2009-04-23 | Fumiaki Uchiyama | Phage Display By Novel Filamentous Bacteriophage |
| CN101553567A (zh) | 2006-07-21 | 2009-10-07 | 台拉维夫大学拉莫特 | 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法 |
| KR101485202B1 (ko) | 2006-10-11 | 2015-01-22 | 안티토페 리미티드 | Ｔ 세포 에피토프 데이터베이스들 |
| WO2009143470A1 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| AU2009316326A1 (en) | 2008-11-24 | 2010-05-27 | Ramot At Tel-Aviv University Ltd. | Method for treating Parkinson' s disease using filamentous bacteriophage |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| JP2014509514A (ja) | 2011-03-11 | 2014-04-21 | ラモット アット テルアヴィブ ユニヴァーシティ リミテッド | 神経変性タウオパシーを治療するための方法 |
| EP2785364B1 (en) * | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
| MX358755B (es) | 2012-10-02 | 2018-09-03 | Proclara Biosciences Inc | Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides. |
| US9988444B2 (en) * | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| SG11201704427YA (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences Inc | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
-
2015
- 2015-12-02 SG SG11201704427YA patent/SG11201704427YA/en unknown
- 2015-12-02 CN CN201580065696.9A patent/CN107250154A/zh active Pending
- 2015-12-02 MX MX2017007059A patent/MX2017007059A/es unknown
- 2015-12-02 WO PCT/US2015/063476 patent/WO2016090022A1/en not_active Ceased
- 2015-12-02 TW TW104140347A patent/TW201632542A/zh unknown
- 2015-12-02 PT PT158310110T patent/PT3227313T/pt unknown
- 2015-12-02 KR KR1020177017763A patent/KR20170085132A/ko not_active Withdrawn
- 2015-12-02 CA CA2969128A patent/CA2969128A1/en not_active Abandoned
- 2015-12-02 BR BR112017011530A patent/BR112017011530A2/pt not_active Application Discontinuation
- 2015-12-02 EP EP15831011.0A patent/EP3227313B1/en active Active
- 2015-12-02 JP JP2017529043A patent/JP6730988B2/ja active Active
- 2015-12-02 EA EA201791212A patent/EA201791212A1/ru unknown
- 2015-12-02 PL PL15831011T patent/PL3227313T3/pl unknown
- 2015-12-02 ES ES15831011T patent/ES2910017T3/es active Active
- 2015-12-02 AU AU2015358504A patent/AU2015358504A1/en not_active Abandoned
- 2015-12-02 DK DK15831011.0T patent/DK3227313T3/da active
- 2015-12-02 US US15/532,820 patent/US10722551B2/en active Active
- 2015-12-03 AR ARP150103956A patent/AR102890A1/es unknown
-
2017
- 2017-05-22 IL IL252426A patent/IL252426A0/en unknown
- 2017-05-31 PH PH12017501004A patent/PH12017501004A1/en unknown
-
2020
- 2020-02-19 JP JP2020026300A patent/JP2020073610A/ja not_active Withdrawn
- 2020-06-18 US US16/905,128 patent/US11723951B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538407A5 (enExample) | ||
| JP2016526044A5 (enExample) | ||
| JP2012530055A5 (enExample) | ||
| EP2361638B1 (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| US8440799B2 (en) | Methods of purifying anti A β antibodies | |
| JP6029280B2 (ja) | Ｄ−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物 | |
| JP7722990B2 (ja) | アミロイド沈着物を標的化するための修飾免疫グロブリン | |
| CN108431044A (zh) | 抗age抗体及其使用方法 | |
| JP6283366B2 (ja) | アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用 | |
| BRPI1012853B1 (pt) | Anticorpo humanizado específico para a forma protofibrilar do peptídeo beta-amiloide e seu processo de produção, composição farmacêutica, polinucleotídeo e vetor recombinante | |
| US11723951B2 (en) | Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal | |
| US12247055B2 (en) | General amyloid interaction motif (GAIM) | |
| WO2020069050A2 (en) | Methods of treating neurodegenerative diseases | |
| Tai et al. | The tau oligomer antibody APNmAb005 detects early-stage pathological tau enriched at synapses and rescues neuronal loss in long-term treatments | |
| CN101325972B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 | |
| Wu et al. | Conformation-dependent antibodies as tools for characterization of amyloid protein aggregates | |
| US20110002945A1 (en) | Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins | |
| HK40110180A (en) | General amyloid interaction motif (gaim) | |
| Griner | Cross Amyloid interfaces of Amyloid Beta | |
| HK40049127B (en) | General amyloid interaction motif (gaim) | |
| HK40049127A (en) | General amyloid interaction motif (gaim) | |
| HK1124532B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 | |
| HK1249520B (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal | |
| HK1204579B (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1161141B (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties |